Biologicals for Colorectal Cancer Metastases

C. Bokemeyer, I. Bondarenko, A. Makhson, J. T. Hartmann, J. Aparicio, M. Zampino, S. Donea, H. Ludwig, A. Zubel, P. Koralewski, Cetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) versus FOLFOX-4 in the first-line treatment of metastatic colorectal cancer (mCRC): OPUS, a randomized phase II study Journal of Clinical Oncology. ,vol. 25, pp. 4035- 4035 ,(2007) , 10.1200/JCO.2007.25.18_SUPPL.4035

C. Bokemeyer, I. Bondarenko, J. T. Hartmann, F. G. De Braud, C. Volovat, J. Nippgen, C. Stroh, I. Celik, P. Koralewski, KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: The OPUS experience Journal of Clinical Oncology. ,vol. 26, pp. 4000- 4000 ,(2008) , 10.1200/JCO.2008.26.15_SUPPL.4000

D. Hollis, S. Sutherland, R. Goldberg, S. Alberts, A. Benson, J. Wade, R. Schilsky, R. Mayer, A. Venook, D. Niedzwiecki, Phase III study of irinotecan/5FU/LV (FOLFIRI) or oxaliplatin/5FU/LV (FOLFOX) ± cetuximab for patients (pts) with untreated metastatic adenocarcinoma of the colon or rectum (MCRC): CALGB 80203 preliminary results Journal of Clinical Oncology. ,vol. 24, pp. 3509- 3509 ,(2006) , 10.1200/JCO.2006.24.18_SUPPL.3509

Michael D’Angelica, Peter Kornprat, Mithat Gonen, Ki-Young Chung, William R. Jarnagin, Ronald P. DeMatteo, Yuman Fong, Nancy Kemeny, Leslie H. Blumgart, Leonard B Saltz, Lack of Evidence for Increased Operative Morbidity After Hepatectomy with Perioperative Use of Bevacizumab: A Matched Case-Control Study Annals of Surgical Oncology. ,vol. 14, pp. 759- 765 ,(2007) , 10.1245/S10434-006-9074-0

Maria Giulia Zampino, Elena Magni, Cristian Massacesi, Alberto Zaniboni, Angelo Martignetti, Laura Zorzino, Katia Lorizzo, Luigi Santoro, Sabrina Boselli, Filippo de Braud, First clinical experience of orally active epidermal growth factor receptor inhibitor combined with simplified FOLFOX6 as first-line treatment for metastatic colorectal cancer Cancer. ,vol. 110, pp. 752- 758 ,(2007) , 10.1002/CNCR.22851

G. Folprecht, J. Tabernero, C.-H. Kohne, C. Zacharchuk, L. Paz-Ares, F. Rojo, S. Quinn, E. Casado, R. Salazar, R. Abbas, C. Lejeune, I. Marimon, J. Andreu, U. Ubbelohde, H. Cortes-Funes, J. Baselga, Phase I Pharmacokinetic/Pharmacodynamic Study of EKB-569, an Irreversible Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Combination with Irinotecan, 5-Fluorouracil, and Leucovorin (FOLFIRI) in First-Line Treatment of Patients with Metastatic Colorectal Cancer Clinical Cancer Research. ,vol. 14, pp. 215- 223 ,(2008) , 10.1158/1078-0432.CCR-07-1053

F Di Fiore, F Blanchard, F Charbonnier, F Le Pessot, A Lamy, M P Galais, L Bastit, A Killian, R Sesboüé, J J Tuech, A M Queuniet, B Paillot, J C Sabourin, F Michot, P Michel, T Frebourg, Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. British Journal of Cancer. ,vol. 96, pp. 1166- 1169 ,(2007) , 10.1038/SJ.BJC.6603685

Thomas Gruenberger, Birgit Gruenberger, Werner Scheithauer, Neoadjuvant Therapy With Bevacizumab Journal of Clinical Oncology. ,vol. 24, pp. 2592- 2593 ,(2006) , 10.1200/JCO.2005.05.2910

R. K. Jain, Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy Science. ,vol. 307, pp. 58- 62 ,(2005) , 10.1126/SCIENCE.1104819

Mario E. Lacouture, Mechanisms of cutaneous toxicities to EGFR inhibitors. Nature Reviews Cancer. ,vol. 6, pp. 803- 812 ,(2006) , 10.1038/NRC1970